POLLOGEN GENEO+U OXYGENEO AND TRIPOLAR OPTIONS
GUI Version: 2.2.10
Includes two applicators:
Unit turns on. Good condition, see photos.
Please reach out with any questions.
Pollogen GeneO+U OxyGeneo and Tripolar Options Abstract
Background: Oxygenation of the skin has been shown to improve cell growth and cell biosynthesis, which can subsequently improve the skin’s appearance.1,2 However, the majority of skin oxygenation techniques are invasive.3,4 A noninvasive skin oxygenation treatment, also known as a carboxytherapy facial, with TriPollar® radiofrequency device has emerged called OxyGeneo™, which is provided by the geneO+™ skin care platform (Pollogen GeneO+U OxyGeneo and Tripolar Options). Objective: This study addresses the clinical effectiveness of the aforementioned noninvasive skin oxygenation treatment on skin texture, fine lines/wrinkles, and skin pigmentation over an eight-week time period. Methods and materials: Ten patients with fine lines, wrinkles, hyperpigmentation, and rough skin texture received six weekly treatments over a two-month period. Five patients received NeoRevive™ and five received NeoBright™ topical infusions, with the selection made according to each individual’s skin conditions and type. These patients were evaluated using the VISIA complexion analysis system (Canfield Scientific, Inc., Parsippany, New Jersey) and patient and evaluator assessments and satisfaction surveys. Results: Each individual measurement varied by patient, but the change in value of each category that was assessed prior to treatment and post-treatment indicated an improvement. All patients in the study stated an improvement in overall skin appearance, skin texture, brightness, and shininess. Nine out of the 10 patients reported that their skin was softer and had a more youthful appearance after the treatments, and seven out of the 10 patients saw a minor improvement in fine lines and wrinkles. Lastly, five out of the 10 patients noticed an improvement in skin pigmentation. Conclusion: The results indicated the combination of the three-in-one OxyGeneo treatment of exfoliation, infusion and oxygenation using TriPolar radiofrequency prompted an improvement in skin texture and tone. This is an optimal procedure that can be implemented in patients looking for noninvasive, safe, and effective rejuvenation treatments with no associated downtime post-procedure.
POLLOGEN GENEO+U OXYGENEO AND TRIPOLAR OPTIONS Keywords: OxyGeneo, exfoliation, infusion, oxygenation, Bohr effect, TriPollar, skin rejuvenation, aging skin
During the aging process in the skin, there is a general atrophy of the extracellular matrix and a decrease in the number of fibroblasts and levels of collagen and elastin. Research has shown that increasing optimal oxygen delivery to the skin improves cell growth and cell biosynthesis.1,2 Studies have also suggested that increased oxygenation stimulates fibroblast proliferation and keratinocyte differentiation.6 This has stimulated a growing interest in oxygen-based skin treatments. However, the stability of oxygen-based compounds in topical formulations has been questioned, as has their ability to penetrate the stratum corneum effectively.
The OxyGeneo™ treatment (OGT, Pollogen Ltd., Tel Aviv, Israel) provided by the geneO+™ skin care platform (Pollogen Ltd., Tel Aviv, Israel) is a novel, noninvasive treatment that invokes skin oxygenation in combination with mechanical exfoliation and skin infusion.7 The treatment includes the performance of a light exfoliation with a simultaneous infusion of active ingredients via two treatment gels, NeoRevive™ (NR) for drier skin and skin rejuvenation and NeoBright™ (NB) for oiler skin and skin brightening, respectively. The exfoliation is preceded by TriPollar® radiofrequency (RF) technology8 (Pollogen Ltd., Tel Aviv, Israel) for noninvasive dermal remodeling, and is finished with the exchange of the exfoliation head for a massager head to provide the skin with a more vibrant, glowing appearance.
POLLOGEN GENEO+U OXYGENEO AND TRIPOLAR OPTIONS The use of carbon dioxide (CO2) through the Bohr effect has been used in subcutaneous CO2 injections in order to ensure oxygen delivery to the skin tissues.3 However, transcutaneous CO2 injections are invasive, have many side effects, and can be impractical to apply to the entire face.3,4 There is a need for noninvasive CO2 treatments that can enhance neocollagenesis with minimal pain or downtime for the patient. OGT is a noninvasive CO2 treatment that utilizes the Bohr effect. The Bohr effect is represented by an incrementation in the partial pressure of CO2 or decrease in pH as seen as a rightward shift of the O2-hemoglobin dissociation curve. CO2 incites local cutaneous vasodilation and thereby increases incremental regional blood flow, which in turn increases the oxygen availability in the skin.9 Transcutaneous CO2 delivery has been well-documented and studied. CO2 is water-soluble, making it an ideal gas for transcutaneous delivery.10
The light mechanical exfoliation provided by OGT uses a widely employed microdermabrasion system that increases skin permeability to enhance the infusion of active ingredients.11 This technology also increases circulation and oxygenation in the treated areas, enhancing the delivery and absorption of the active ingredients.12 In addition, OGT uses the RF technology to heat the dermal layer through electromagnetic energy. This, combined with the exfoliation, induces the activation of fibroblasts for the production of new collagen fibers. The result is skin tightening and an improvement of wrinkles over time.13
The purpose of our study was to determine if the OGT could improve skin texture in a short period of time. We treated 10 patients with six weekly treatments over a two-month period. Five patients received NR and five received NB topical infusions according to their individual skin conditions and type. These patients were evaluated using the VISIA complexion analysis system (Canfield Scientific, Inc., Parsippany, New Jersey) and patient and evaluator assessments and satisfaction surveys.
This was a single-center study that involved 10 healthy female patients 27 to 61 years of age.Study protocol followed the ethical principles of the Helsinki Declarion. Patients gave informed consent to undergo six weekly OGTs with the geneO+ platform device (Figure 1). Patients also gave photoconsent. The inclusion criteria were healthy female patients of any racial/ethnic origin with Fitzpatrick skin types I to VI who were aged between 25 years and 65 years. Exclusion criteria were a current presence or history of skin cancer; pregnancy; lactation; active dermatologic conditions in the treatment area; vascular disorders in the treatment area; recent use of resurfacing products or treatments on the treatment area; known allergies to cosmetics or other products; and/or the performance of any recent surgical, ablative, or invasive procedure including fillers or botulinum toxin.